Related Experiment Video
Updated: Jul 15, 2026

Using a Pan-Viral Microarray Assay Virochip to Screen Clinical Samples for Viral Pathogens
Published on: April 27, 2011
Letter to the Editor in response to Chen et al. 2020
Jaya Ponnampalam1, George Seligmann2, Tanaya Gandhi2
1University College London Medical School, 74 Huntley S, London, WC1E 6DE, UK. jaya.ponnampalam.15@ucl.ac.uk.
Insights
Cytokine profiles, including Interleukin-6 (IL-6), are linked to COVID-19 severity. Further research on critically ill patients and tocilizumab is needed to confirm survival benefits and identify new therapeutic targets.
Area of Science:
- Immunology
- Infectious Diseases
- Critical Care Medicine
Background:
- The immunopathogenesis of COVID-19 involves a complex interplay of cytokines.
- Elevated pro-inflammatory cytokines, known as a "cytokine storm," are associated with severe COVID-19.
- Understanding these cytokine profiles is crucial for predicting disease severity and guiding treatment.
Discussion:
- Del Valle et al. confirmed IL-6's association with disease severity and also noted the significance of IL-8.
- Discrepancies in findings may stem from differing methodologies used to assess disease severity.
Key Insights:
- IL-6 is a significant predictor of COVID-19 severity.
- IL-8 also plays a role in disease progression, though its significance may vary based on study methods.
Outlook:
- Further studies involving critically ill patients are essential to analyze mortality rates and enhance clinical relevance.
- Investigating other pro-inflammatory cytokines could reveal novel therapeutic targets for COVID-19 lung injury.
Abstract:
We would like to comment on the article entitled "Association between cytokine profiles and lung injury in COVID-19 pneumonia" by Li-Da Chen and colleagues, with respect to emerging data regarding the immunopathogenesis of COVID-19. Chen et al. demonstrated the relevance of IL-2R, IL-6 and TNF-α in the cytokine storm and IL-6 as an independent predictor for COVID-19 severity. Del Valle et al. corroborated these findings with regard to IL-6 and disease severity, however, they also showed IL-8 to be of significance. This may be explained by the varying techniques used by the two studies to determine severity. Further studies including critically ill patients and the analysis of mortality rates in this patient cohort would greatly enhance the clinical relevance of these findings. As speculated by Chen et al., early studies on the use of tocilizumab in COVID-19 patients were promising, however, full results from ongoing trials are required to confirm a survival benefit in patients treated with tocilizumab. Moreover, investigating the roles of other pro-inflammatory cytokines and their impact on disease severity could potentially inform novel therapeutic targets.
Related Concept Videos
Feedback Inhibition
Cross-reactivity
Altruism
Correspondence Bias

